 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | ALZN002 / Alzamend Neuro
Enrollment closed, IO biomarker: Study in Subjects With Mild-to-Moderate Alzheimer's Dementia (clinicaltrials.gov) - Apr 15, 2024
P1/2, N=30, Active, not recruiting, Sponsor: Alzamend Neuro, Inc.
Recruiting --> Active, not recruiting
- || ALZN002 / Alzamend Neuro
Enrollment open, IO biomarker: Study in Subjects With Mild-to-Moderate Alzheimer's Dementia (clinicaltrials.gov) - Aug 1, 2023
P1/2, N=30, Recruiting, Sponsor: Alzamend Neuro, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || ALZN002 / Alzamend Neuro
New P1/2 trial, IO biomarker: Study in Subjects With Mild-to-Moderate Alzheimer's Dementia (clinicaltrials.gov) - Apr 28, 2023
P1/2, N=30, Not yet recruiting, Sponsor: Alzamend Neuro, Inc.
- ||| AL001 / GSK, LiProSal (AL001) / Alzamend Neuro, AL002 / Alzamend Neuro
@AlzamendNeuro CEO Stephan Jackman on a potential cure (AL001 & AL002) (lithium 2.0) @alzfdn @TheADDF @alzassociation @alzheimerssoc @DBSAlliance @IntlBipolar (Twitter) - Dec 24, 2021